Key Points
- CFO Ryan Savitz sold 20,000 shares on December 4 at an average price of $45.18 for a total of $903,600, and previously sold 20,000 shares on September 9 at $35 for $700,000.
- The stock opened at $44.26 with a market cap of $1.90 billion and a 1-year high of $45.46, while the company reported a quarterly EPS of ($0.97) that missed estimates and showed deeply negative margins.
- Analysts hold a consensus of "Moderate Buy" with an average target of $63.43 (nine Buys, one Sell), and several firms have recently raised price targets, including Guggenheim and Baird.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) CFO Ryan Savitz sold 20,000 shares of the stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $45.18, for a total value of $903,600.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Ryan Savitz also recently made the following trade(s):
- On Tuesday, September 9th, Ryan Savitz sold 20,000 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $35.00, for a total value of $700,000.00.
Dianthus Therapeutics Price Performance
Shares of NASDAQ DNTH opened at $44.26 on Friday. The company has a market cap of $1.90 billion, a price-to-earnings ratio of -12.72 and a beta of 1.56. The stock's 50-day moving average is $37.71 and its two-hundred day moving average is $27.97. Dianthus Therapeutics, Inc. has a 1-year low of $13.36 and a 1-year high of $45.46.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.11). Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. The company had revenue of $0.40 million during the quarter, compared to analysts' expectations of $0.58 million. Equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on DNTH shares. Robert W. Baird increased their price objective on shares of Dianthus Therapeutics from $50.00 to $67.00 and gave the company an "outperform" rating in a research report on Tuesday, September 9th. Wedbush boosted their target price on shares of Dianthus Therapeutics from $44.00 to $46.00 and gave the stock an "outperform" rating in a research note on Thursday, November 6th. Weiss Ratings reissued a "sell (d-)" rating on shares of Dianthus Therapeutics in a report on Wednesday, October 8th. Stifel Nicolaus lifted their price target on Dianthus Therapeutics from $52.00 to $65.00 and gave the stock a "buy" rating in a report on Friday, September 12th. Finally, Guggenheim upped their price objective on Dianthus Therapeutics from $92.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, September 9th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $63.43.
Get Our Latest Stock Analysis on DNTH
Institutional Investors Weigh In On Dianthus Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the stock. TCG Crossover Management LLC boosted its stake in Dianthus Therapeutics by 11.7% in the third quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company's stock valued at $65,975,000 after acquiring an additional 175,000 shares in the last quarter. Vivo Capital LLC acquired a new stake in shares of Dianthus Therapeutics during the third quarter worth about $13,930,000. Polar Capital Holdings Plc purchased a new stake in shares of Dianthus Therapeutics in the 3rd quarter valued at about $29,434,000. Nantahala Capital Management LLC acquired a new stake in shares of Dianthus Therapeutics in the 3rd quarter valued at about $14,756,000. Finally, Jain Global LLC acquired a new stake in shares of Dianthus Therapeutics in the 3rd quarter valued at about $438,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.
Dianthus Therapeutics Company Profile
(
Get Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
